Premium
Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs
Author(s) -
KielerFerguson Heidi M.,
Fréchet Jean M. J.,
Szoka Jr Francis C.
Publication year - 2013
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1209
Subject(s) - camptothecin , nanomedicine , drug delivery , drug , liposome , pharmacology , cisplatin , paclitaxel , anticancer drug , medicine , nanotechnology , chemotherapy , chemistry , materials science , nanoparticle , organic chemistry
For the past 40 years, liposomal and polymeric delivery vehicles have been studied as systems capable of modulating the cytotoxicity of small molecule chemotherapeutics, increasing tumor bearing animal survival times, and improving drug targeting. Although a number of macromolecular‐drug conjugates have progressed to clinical trials, tuning drug release to maintain efficacy in conjunction with controlling drug toxicity has prevented the clinical adoption of many vehicles. In this article, we review the motivations for and approaches to polymer and liposomal delivery with regard to camptothecin and cisplatin delivery. WIREs Nanomed Nanobiotechnol 2013, 5:130–138. doi: 10.1002/wnan.1209 This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease